ʻO Rosuvastatin Calcium
瑞舒伐他汀钙 | ʻO Rosuvastatin Calcium | 147098-20-2 | I loko o ka Hale/CEP |
RSM(Crystal) | 147118-40-9 | I-Hale | |
RSM(Kūpono) | 147118-40-9 | I-Hale | |
RSP | — | I-Hale | |
RS-8 | 147118-36-3 | I-Hale | |
RS-8-1 | 147118-37-4 | I-Hale | |
TP-8 | 131466-61-0 | I-Hale | |
TP-11 | 147118-35-2 | I-Hale | |
TP-13 | 147118-39-6 | I-Hale | |
RS-10 | 289042-12-2 | I-Hale | |
RS-11 | 355806-00-7 | I-Hale |
wehewehe
ʻO Rosuvastatin Calcium (BANM, JAN, USAN) ʻike ʻia ʻo Rosuvastatin ma US. a me ka mea hoʻokūkū hoʻokūkū HMG-CoA reductase me kahi IC50 o 11 nM[1]. Hoʻopaʻa ikaika ʻo Rosuvastatin Calcium i ke kanaka ether-a-go-go related gene (hERG) i kēia manawa me kahi IC50 o 195 nM, hoʻopaneʻe i ka repolarization cardiac, a no laila e hoʻolōʻihi ai i nā hana hiki ke hana (APDs) a hoʻoponopono i ka wā QT interval (QTc) [2]. Hoʻemi ʻo Rosuvastatin Calcium i ka hōʻike ʻana o ka hERG makua a me ka hoʻopili ʻana o ka protein haʻalulu wela 70 (Hsp70) me ka protein hERG. ʻO Rosuvastatin Calcium ka mea maikaʻi loa i ka hoʻohaʻahaʻa ʻana i ka lipoprotein haʻahaʻa haʻahaʻa (LDL) cholesterol, triglycerides, a me nā pae protein C-reactive [3].
ʻIke hou aʻe e pili ana i nā hui inoa lāʻau: International Nonproprietary Names.
Hoʻolaha Nui: Aia ka ʻikepili honua ʻo Drugs.com ma ka hoʻokuʻu BETA. ʻO ia ke ʻano o ka hoʻomohala ʻia ʻana a loaʻa paha nā hemahema. ʻAʻole i manaʻo ʻia ma ke ʻano he pani no ka ʻike a me ka hoʻoholo ʻana o kāu kauka, lāʻau lapaʻau a i ʻole nā mea mālama ola kino ʻē aʻe. ʻAʻole pono e manaʻo ʻia he palekana, kūpono a kūpono paha ka hoʻohana ʻana i kekahi lāʻau lapaʻau ma kekahi ʻāina. E kūkākūkā me kāu kauka mālama ola ma mua o ka lawe ʻana i kekahi lāʻau lapaʻau.
I ka US, ʻo Rosuvastatin (rosuvastatin systemic) he lālā ia o ka papa lāʻau statins a hoʻohana ʻia e mālama i ka Atherosclerosis, High Cholesterol, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Hyperlipoproteinemia, Hyperlipoproteinemia Type IIa - Elevated LDL, Hyperlipoproteinemia Type. IIb - Hoʻokiʻekiʻe LDL VLDL, Hyperlipoproteinemia Type III - Hoʻokiʻekiʻe beta-VLDL IDL, Hyperlipoproteinemia Type IV - Hoʻokiʻekiʻe VLDL, Hypertriglyceridemia a me ka pale ʻana i ka maʻi cardiovascular.
Kāpae
He mea hoʻokūkū hoʻokūkū hoʻokūkū o HMG-CoA reductase, ʻo ia hoʻi he antilipemic.
Waihona
Pauda | -20°C | 3 makahiki |
4°C | 2 makahiki | |
I ka solvent | -80°C | 6 mahina |
-20°C | 1 mahina |
ʻO ke kinona





Manaʻo18Nā papahana Loiloi Kūlike Kūlike i ʻae ʻia4, a6apono ʻia nā papahana.

Ua hoʻokumu ka ʻōnaehana hoʻokele maikaʻi honua kiʻekiʻe i ke kumu kūʻai.

Holo ka nānā ʻana i ka maikaʻi ma ke ola holoʻokoʻa o ka huahana e hōʻoia i ka maikaʻi a me ka hopena therapeutic.

Kākoʻo ka hui ʻoihana Regulatory Affairs i nā koi maikaʻi i ka wā o ke noi a me ke kākau inoa ʻana.


Kolea Countec Bottled Packaging Line


ʻO Taiwan CVC Bottled Packaging Line


Italia CAM Board Packaging Line

Mekini Fette Compacting German

ʻO Iapana Viswill Tablet ʻIke

Keena Mana o DCS

